Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Revenue (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Revenue for 11 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • Quarterly Revenue rose 32.84% to $1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 billion through Dec 2025, up 40.23% year-over-year, with the annual reading at $5.3 billion for FY2025, 40.23% up from the prior year.
  • Revenue for Q4 2025 was $1.5 billion at BeOne Medicines, up from $1.4 billion in the prior quarter.
  • The five-year high for Revenue was $1.5 billion in Q4 2025, with the low at $150.0 million in Q2 2021.
  • Average Revenue over 5 years is $710.2 million, with a median of $620.1 million recorded in 2021.
  • The sharpest move saw Revenue surged 1063.82% in 2021, then plummeted 49.39% in 2022.
  • Over 5 years, Revenue stood at $214.0 million in 2021, then soared by 77.63% to $380.1 million in 2022, then soared by 66.91% to $634.4 million in 2023, then soared by 77.78% to $1.1 billion in 2024, then surged by 32.84% to $1.5 billion in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $1.5 billion, $1.4 billion, and $1.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.